“This is important because it can help doctors make better decisions about which medicines to use for older patients with type 2 diabetes,” says Bowen Tang, a PhD student in Sara Hägg‘s research group at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet. “However, proper randomised trials are needed to establish with certainty that GLP-1 agonists reduce the risk of dementia.”
The study was funded by the Swedish Research Council, Karolinska Institutet, the National Institute on Aging, the National Institutes of Health, and Riksbankens Jubileumsfond. There are no reported conflicts of interest.
Publication
“Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study”, Bowen Tang, Arvid Sjölander, Jonas W. Wastesson, Géric Maura, Pierre-Olivier Blotiere, Máté Szilcz, Jonathan K. L. Mak, Chenxi Qin, Michael Alvarsson, Dorota Religa, Kristina Johnell, Sara Hägg, eClinicalMedicine, online 21 June 2024, doi: 10.1016/j.eclinm.2024.102689.